Related Experiment Video
Updated: Jun 12, 2025
07:26
Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
Published on: July 14, 2021
5.0K
Extracellular Vesicle-Derived Non-Coding RNAs: Key Mediators in Remodelling Heart Failure
Jiayi Zhao1,2, Huang Huang1,2
1Department of Cardiovascular Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Current Issues in Molecular Biology
|September 27, 2024
Summary
Extracellular vesicle non-coding RNAs (EV-ncRNAs) show promise for diagnosing and treating heart failure (HF). These molecules, including microRNAs and circular RNAs, are key in cell communication and HF progression, offering new therapeutic strategies.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiology
Background:
- Heart failure (HF) is a critical global health issue with limited curative treatments.
- Extracellular vesicles (EVs) are crucial for intercellular communication, transporting biomolecules like RNA, DNA, and proteins.
- Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs), are found in EVs and influence HF pathophysiology.
Purpose of the Study:
- To review the mechanisms of EV-ncRNAs in heart failure.
- To highlight the diagnostic potential of differentially expressed miRNAs and circRNAs in cardiovascular disease.
- To summarize advances in EV engineering for HF diagnosis and therapy.
Main Methods:
- Literature review focusing on EV-ncRNA mechanisms in HF.
- Analysis of studies on miRNA and circRNA as biomarkers for cardiovascular diseases.
- Examination of recent research on EV-based diagnosis and treatment strategies for HF.
Main Results:
- EV-ncRNAs play a significant role in modulating HF in recipient cells.
- Differentially expressed miRNAs and circRNAs within EVs show potential as biomarkers for HF.
- EVs can be engineered for targeted delivery, offering novel therapeutic approaches for HF.
Conclusions:
- EV-ncRNAs represent a promising frontier for the diagnosis and treatment of heart failure.
- Further research into EV engineering is crucial for developing effective HF therapies.
- Understanding EV-ncRNA interactions provides novel insights into cardiovascular disease mechanisms.
Keywords:
biogenesisengineered extracellular vesiclesexosomeextracellular vesiclesheart failuremicroRNAnon-coding RNAMore Related Videos
09:37Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
27.8K
10:21Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
10.0K
Related Concept Videos
01:29Heart Failure II: Pathophysiology
3
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:22Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
01:30Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
01:27Heart Failure I: Introduction
2
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
2